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Chitinase 3-like 1 (CHI3L1) has been proposed as a biomarker associated with the conversion to clinically deﬁnite multiple
sclerosis in patients with clinically isolated syndromes, based on the ﬁnding of increased cerebrospinal ﬂuid CHI3L1 levels in
clinically isolated syndrome patients who later converted to multiple sclerosis compared to those who remained as clinically
isolated syndrome. Here, we aimed to validate CHI3L1 as a prognostic biomarker in a large cohort of patients with clinically
isolated syndrome. This is a longitudinal cohort study of clinically isolated syndrome patients with clinical, magnetic resonance
imaging, and cerebrospinal ﬂuid data prospectively acquired. A total of 813 cerebrospinal ﬂuid samples from patients with
clinically isolated syndrome were recruited from 15 European multiple sclerosis centres. Cerebrospinal ﬂuid CHI3L1 levels were
measured by enzyme-linked immunosorbent assay. Multivariable Cox regression models were used to investigate the association
between cerebrospinal ﬂuid CHI3L1 levels and time to conversion to multiple sclerosis and time to reach Expanded Disability
Status Scale 3.0. CHI3L1 levels were higher in patients who converted to clinically deﬁnite multiple sclerosis compared to patients
who continued as clinically isolated syndrome (P = 8.1  1011). In the Cox regression analysis, CHI3L1 levels were a risk factor
for conversion to multiple sclerosis (hazard ratio = 1.7; P = 1.1  105 using Poser criteria; hazard ratio = 1.6; P = 3.7  106 for
McDonald criteria) independent of other covariates such as brain magnetic resonance imaging abnormalities and presence of
cerebrospinal ﬂuid oligoclonal bands, and were the only signiﬁcant independent risk factor associated with the development of
disability (hazard ratio = 3.8; P = 2.5  108). High CHI3L1 levels were associated with shorter time to multiple sclerosis
(P = 3.2  109 using Poser criteria; P = 5.6  1011 for McDonald criteria) and more rapid development of disability
(P = 1.8  1010). These ﬁndings validate cerebrospinal ﬂuid CHI3L1 as a biomarker associated with the conversion to multiple
sclerosis and development of disability and reinforce the prognostic role of CHI3L1 in patients with clinically isolated syndrome.
We propose that determining cerebrospinal ﬂuid chitinase 3-like 1 levels at the time of a clinically isolated syndrome event will help
identify those patients with worse disease prognosis.
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Introduction
In a previous screening mass spectrometry-based proteomic
study in pooled CSF samples from patients with clinically
isolated syndromes (CIS), increased levels of chitinase 3-like
1 (CHI3L1) were found in CIS patients who converted to
clinically deﬁnite multiple sclerosis compared with patients
who continued as CIS (Comabella et al., 2010).
Measurement of CHI3L1 levels by enzyme-linked immuno-
sorbent assay (ELISA) in individual CSF samples from pa-
tients with CIS resulted in similar ﬁndings, and increased
levels of CHI3L1 at the time of the CIS event were asso-
ciated with shorter time to clinically deﬁnite multiple scler-
osis and disability progression during follow-up
(Comabella et al., 2010). In this initial study, the classiﬁ-
cation of CIS patients was performed according to extremes
of outcome, and multiple sclerosis non-converters were pa-
tients with negative CSF oligoclonal bands and normal
brain MRI at baseline and after 5 years of follow-up. On
the other hand, multiple sclerosis converters were patients
who also had positive oligoclonal bands and three or four
Barkhof criteria in the baseline brain MRI (Comabella
et al., 2010). It remained unknown, however, whether
CSF CHI3L1 ﬁndings in these two subgroups of CIS pa-
tients could also be extrapolated to any patient attending a
multiple sclerosis outpatient clinic with a CIS suggestive of
CNS demyelination. With this in mind, our main objective
was to perform a validation study of CHI3L1 as a prog-
nostic biomarker associated with the conversion to multiple
sclerosis and disease severity in CSF samples from a large
cohort of CIS patients from different multiple sclerosis cen-
tres. In a second part of the study, we investigated the cell
source of CHI3L1 in brain tissue and CSF samples from
patients with multiple sclerosis.
Patients and methods
Patients with clinically isolated
syndromes
This is a multicentre collaborative study of patients presenting
for the ﬁrst time with monophasic neurological symptoms of
the type observed in multiple sclerosis. Inclusion criteria were:
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a CIS suggestive of CNS demyelination involving the optic
nerve, brainstem, spinal cord, or other topography that was
not attributable to other diseases; and entry window of 3
months since onset of symptoms. A total of 813 patients
with CIS were recruited from 15 European multiple sclerosis
centres. The study was approved by the corresponding local
ethics committees and participants gave written informed
consent.
MRI, CSF and clinical assessments were performed in each
participating centre as part of their diagnostic workup.
Patients were seen every 3 to 6 months and instructed to
report any new or worsening of pre-existing symptoms.
Brain MRI was performed during the ﬁrst 5 months after
the CIS event and repeated after 12 months and 5 years of
follow-up. The number of Barkhof criteria (Barkhof et al.,
1997; Tintore et al., 2008), number of T2 lesions (recoded
into three different categories: 0 lesions / 1–8 lesions / 9 or
more lesions), and number of gadolinium enhancing lesions
(recoded into two categories: 0 lesions / 1 or more lesions)
in the baseline MRI were scored. Immunoglobulin G
(IgG) oligoclonal bands were determined by isoelectric focus-
ing combined with immunoblotting of matched serum and CSF
sample pairs. Disability was evaluated according to the
Expanded Disability Status Scale (EDSS) in each visit and
only EDSS taken during stability periods was considered.
EDSS scores collected during relapses were not included. The
cut-off for deﬁning the presence of disability was established
when EDSS was superior or equal to 3.0 and maintained at
two time points during the follow-up. An EDSS of 3.0 repre-
sents a clear milestone and corresponds to a patient who is
fully ambulatory but has moderate disability in at least one
system function or mild disability in three or four functional
systems. Time of follow-up was calculated as the difference
between the date of the last visit and the date of the CIS
event. A diagnosis of conversion to multiple sclerosis according
to Poser criteria was made when new symptoms occurred
after an interval of at least 1 month and only when other
diagnoses had been excluded (Poser et al., 1983). A diagnosis
of conversion to multiple sclerosis as deﬁned by the 2005
McDonald criteria was made when patients fulﬁlled the MRI
deﬁnitions for dissemination in time and space; or when pa-
tients had a second clinical attack (Polman et al., 2005).
Evidence of dissemination in space was provided by the
presence of three of four MRI Barkhof parameters; or by the
presence of at least two T2 lesions together with oligoclonal
bands. Dissemination in time was satisﬁed when at least
one new T2 lesion had appeared in the follow-up MRI
(Polman et al., 2005). Brain parenchymal fraction was calcu-
lated as the ratio of brain parenchymal tissue volume to the
total intracranial volume. Data on the brain parenchymal
fraction were available at baseline and after 1 and 5 years of
follow-up in a subgroup of 149 CIS patients (all from the
Centre d’Esclerosi Mu´ltiple de Catalunya – Cemcat,
Barcelona). The number of patients who received immunomo-
dulatory treatment between the CIS event and the date of
conversion to multiple sclerosis for converters, and during
the follow-up time for multiple sclerosis non-converters was
recorded.
Longitudinal clinical, CSF, and MRI information from CIS
patients was prospectively acquired in the different participat-
ing centres. The 2005 McDonald criteria were retrospectively
applied to this prospectively acquired data set.
A summary of demographic and clinical characteristics of
the CIS cohort broken down by participating centre is pre-
sented in Table 1.
Control subjects
For comparison purposes, a cohort of 559 control subjects
[438 non-inﬂammatory neurological disease controls (non-
INDC) and 121 inﬂammatory neurological disease controls
(INDC)] was also included in the study (Teunissen et al.,
2013). Demographic characteristics of the control cohort are
shown in Table 1, and a description of the clinical diagnosis is
detailed in Supplementary Table 1.
CSF sampling
CSF samples were collected by lumbar puncture for routine CSF
diagnostics, which included number of cells, protein concentration,
and determination of the IgG index and oligoclonal bands. The
albumin CSF/serum ratio was studied in a subgroup of 59 CIS
patients (40 patients from the University of Basel, Switzerland; and
19 patients from the University of Ulm, Germany).
CSF samples were centrifuged to remove cells, and the re-
maining volume was aliquoted and conserved at 80C until
used (Teunissen et al., 2009). CSF characteristics of CIS pa-
tients are summarized in Table 1.
Quantification of CSF CHI3L1 levels
Levels of CHI3L1 were measured by ELISA using the
METRA EIA kit (Quidel) in undiluted CSF according to
the manufacturers’ recommendations. ELISA assays were per-
formed in one single centre (Cemcat). Samples were run in
duplicate in a blind manner, and the intra-assay and inter-
assay variabilities were 2.6% and 3.8%, respectively.
CHI3L1 expression in human brain
tissue
Parafﬁn-embedded brain samples of chronic active lesions
from 15 patients with relapsing-remitting multiple sclerosis
and 10 brain tissue samples from non-neurological controls
were provided by the UK Multiple Sclerosis Tissue Bank and
stained with haematoxylin and eosin and Klu¨ver-Barrera for
inﬂammation and demyelination assessment. Multiple sclerosis
lesions were subsequently classiﬁed as chronic active with high
inﬂammatory activity (n = 10) when hypercellularity, abundant
inﬂammatory inﬁltration around blood vessels and at the edge
of the lesion, and active demyelination were found. On the
other hand, multiple sclerosis lesions were classiﬁed as chronic
active with low inﬂammatory activity (n = 5) when hypocellu-
larity, scarce perivascular inﬂammatory inﬁltration and no
active demyelination were observed.
Tissue sections were immunostained with rabbit anti-YKL-
40 (1:100, Quidel); antigen retrieval with Tris-EDTA (TE)
buffer (pH = 9) was needed. Astrocytes were marked with
rabbit anti-GFAP (1:900, Z0334, Dako), macrophages and
microglia with mouse anti-CD68 (1:400, M0876, Dako), and
T lymphocytes with rabbit anti-CD3 (1:100, A0452, Dako).
Double immunostainings were visualized using EnVisionTMG|2
Doublestain System, Rabbit/Mouse (DAB+ /Permanent Red;
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Table 1 Demographic and clinical characteristics of CIS patients and controls with other neurological disorders
included in the study
Patients/controls n Age
(years)
Female/
male
(% female)
Follow-up
time
(years)
CIS typea
ON/BS/
SP/OT
% Treated
patientsb
CSF
OB n/N
(% positive)c
CSF cells
(cells/kl)
CSF
proteins
(g/l)
IgG
index
HC – Barcelona
NC 7 33.7 (7.3) 3/4 (42.8) 5.5 (1.3) 1/2/3/1 42.9 6/7 (85.7) 13.3 (19.7) 41.3 (12.9) 0.7 (0.2)
C 23 27.8 (5.4) 18/5 (78.3) 6.7 (3.1) 4/8/10/1 13.0 17/23 (73.9) 6.8 (7.8) 35.9 (9.1) 0.9 (0.7)
Non-INDC 26 67.5 (15.6) 15/11 (57.7) – – – – – – –
INDC 0 – – – – – – – – –
HRC – Madrid
NC 20 34.3 (12.5) 15/5 (75.0) 4.1 (1.6) 7/6/2/5 10.0 11/20 (55.0) 3.7 (3.8) NA 0.7 (0.3)
C 21 32.8 (6.3) 18/3 (85.7) 5.3 (2.6) 6/3/10/2 4.8 20/21 (95.2) 6.0 (7.4) NA 1.0 (0.6)
Non-INDC 24 48.1 (14.3) 12/12 (50.0) – – – – – – –
INDC 13 42.4 (15.3) 8/5 (61.5) – – – – – – –
UULM - Ulm
NC 12 38.9 (11.0) 8/4 (66.6) 2.2 (1.8) 8/1/2/1 0 10/12 (83.3) 4.7 (5.5) 44.9 (21.3) 0.7 (0.2)
C 17 29.9 (12.5) 11/6 (64.7) 2.5 (2.1) 7/5/3/2 0 17/17 (100) 9.7 (7.4) 41.5 (13.5) 0.9 (0.3)
Non-INDC 14 51.6 (13.5) 6/8 (42.8) – – – – – – –
INDC 0 – – – – – – – – –
EUMC – Rotterdam
NC 16 32.9 (7.0) 12/4 (75.0) 3.7 (2.3) 8/4/4/0 6.3% 8/16 (50.0) 7.5 (8.5) 32.1 (11.0) 1.0 (0.8)
C 13 32.5 (6.9) 11/2 (84.6) 5.7 (3.0) 7/3/1/2 61.5% 12/13 (92.3) 14.0 (16.1) 35.6 (12.7) 1.1 (0.9)
Non-INDC 29 49.5 (17.1) 15/14 (51.7) – – – – – – –
INDC 1 28.0 1/0 (100) – – – – – – –
GM – Madrid
NC 13 34.5 (7.3) 12/1 (92.3) 3.2 (2.2) 6/2/4/1 0% NA 5.2 (7.4) 26.8 (8.3) 0.8 (0.3)
C 9 34.1 (6.6) 7/2 (77.8) 3.2 (2.1) 2/2/2/3 55.6% NA 6.0 (4.4) 26.9 (4.0) 0.8 (0.3)
Non-INDC 13 31.8 (9.0) 9/4 (69.2) – – – – – – –
INDC 0 – – – – – – – – –
PH – Madrid
NC 18 33.4 (7.0) 12/6 (66.7) 4.5 (1.1) 3/7/8/- 27.8% 15/17 (88.2) 3.8 (3.1) 40.1 (8.7) 0.7 (0.3)
C 15 33.9 (9.1) 11/4 (73.3) 5.0 (1.5) 2/7/4/2 13.3% 12/13 (92.3) 6.7 (6.7) 36.7 (12.8) 1.0 (0.5)
Non-INDC 23 43.0 (17.0) 8/15 (34.8) – – – – – – –
INDC 5 50.0 (13.8) 1/4 (20.0) – – – – – – –
HP – Toulouse
NC 19 35.6 (11.9) 15/4 (78.9) 1.4 (1.2) 5/3/9/2 100%d 17/19 (89.5) 6.1 (6.8) 38.4 (16.8) 0.9 (0.5)
C 19 23.9 (7.8) 15/4 (78.9) 3.6 (1.2) 7/6/5/1 100 18/19 (94.7) 6.6 (6.7) 41.2 (10.2) 0.8 (0.3)
Non-INDC 14 41.9 (11.5) 10/4 (71.4) – – – – – – –
INDC 1 57.0 1/0 (100) – – – – – – –
OP – Milan
NC 2 36.5 (3.5) 1/1 (50.0) 5.3 (2.2) 1/-/-/1 0 2/2 (100) 4.3 (2.1) 27.0 (17.0) 0.6 (0.2)
C 9 31.4 (6.8) 3/6 (33.3) 4.2 (2.6) 2/1/1/3e 0 7/8 (87.5) 6.9 (6.5) 33.6 (8.2) 1.1 (0.4)
Non-INDC 2 52.0 (33.9) 2/0 (100) – – – – – – –
INDC 5 33.0 (4.0) 2/3 (40.0) – – – – – – –
USB – Basel
NC 16 38.4 (13.1) 14/2 (87.5) 3.7 (3.2) 8/2/2/4 43.8 11/16 (68.7) 4.6 (6.1) 34.1 (8.3) 0.8 (0.3)
C 24 33.8 (8.7) 18/6 (69.2) 6.3 (3.9) 6/4/8/6 20.8 22/24 (91.7) 10.8 (9.3) 44.0 (13.7) 1.1 (0.6)
Non-INDC 25 38.6 (11.4) 14/11 (56.0) – – – – – – –
INDC 25 51.2 (17.6) 11/14 (44.0) – – – – – – –
MUL – Lublin
NC 1 62.0 1/0 (100) 2.2 -/-/1/- 0 0/1 (0.0) 1.0 28.0 NA
C 22 33.8 (8.5) 10/12 (45.4) 3.8 (2.6) 7/2/4/9 0 14/22 (63.6) 7.8 (11.3) 53.8 (44.6) 1.3 (0.2)
Non-INDC 20 35.7 (12.0) 3/17 (15.0) – – – – – – –
INDC 3 43.7 (22.0) 0/3 (0.0) – – – – – – –
CU – Prague
NC 44 32.2 (9.7) 33/11 (75.0) 3.3 (1.0) 23/3/9/9 45.5 39/44 (88.6) 28.8 (30.3) 30.8 (11.7) 0.8 (0.5)
C 21 31.7 (10.4) 16/5 (76.2) 3.4 (0.9) 7/4/3/7 85.7 21/21 (100) 38.1 (41.1) 32.2 (9.6) 1.1 (0.7)
Non-INDC 35 31.9 (9.1) 25/10 (71.4) – – – – – – –
INDC 9 33.5 (7.8) 5/4 (55.5) – – – – – – –
(continued)
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K5361, Dako) according to the manufacturers’ recommenda-
tions. Slides were counterstained using REAL Haematoxylin
(S2020, Dako) and mounted in Glycerol Mounting Medium
(C0563, Dako).
CHI3L1 expression in CSF cells
CHI3L1 expression was determined by ﬂow cytometry in fresh
CSF samples from ﬁve consecutive untreated multiple sclerosis
patients and ﬁve controls (optic neuropathy, head trauma,
arachnoid cyst, and two controls with neuropathies). The
study was approved by the ethics committee of the Hospital
Ramo´n y Cajal, Madrid.
The following monoclonal antibodies were used for
cell surface staining: control mouse isotypes IgG1-FITC,
IgG1-APC, anti-CD45-PerCP-Cy5.5, anti-CD3-APC, and
anti-CD14-FITC (Becton Dickinson). For intracellular staining,
a polyclonal rabbit antibody anti-human CHI3L1 (Quidel)
and a puriﬁed rabbit IgG (Abcam) were biotinylated with
sulfo-NHS-biotin (Pierce) following the manufacturers’
instructions.
CSF samples were centrifuged at 500g for 15min and cellu-
lar pellets resuspended in 100 ml of PBS, divided in two iden-
tical aliquots, and labelled with optimal concentrations of anti-
CD45-PerCP-Cy5.5 and isotype controls conjugated with
ﬂuorescein isothiocyanate (FITC) and allophycocyanin (APC)
or with anti-CD45-PerCP-Cy5.5, anti CD14-FITC and anti-
CD3-APC for 30min at 4C. For intracellular labelling, cells
were washed in saline and resuspended in 200ml of Cytoﬁx/
CytopermTM (Becton Dickinson). After 20min at 4C, cells
were washed in Perm/Wash buffer, pellets resuspended and
labelled with 1 mg of rabbit IgG-biotin or anti CHI3L1-biotin
Table 1 Continued
Patients/controls n Age
(years)
Female/
male
(% female)
Follow-up
time
(years)
CIS typea
ON/BS/
SP/OT
% Treated
patientsb
CSF
OB n/N
(% positive)c
CSF cells
(cells/kl)
CSF
proteins
(g/l)
IgG
index
MU – Graz
NC 6 35.0 (9.9) 4/2 (66.7) 1.9 (0.6) 3/-/2/1 66.7 6/6 (100) 9.5 (5.0) 39.0 (12.5) 0.8 (0.3)
C 4 33.7 (13.2) 2/2 (50.0) 2.6 (0.4) 1/2/1/- 25.0 4/4 (100) 16.3 (20.0) 38.5 (11.0) 1.8 (0.8)
Non-INDC 15 28.9 (8.0) 8/7 (53.3) – – – – – – –
INDC 5 32.0 (16.1) 1/4 (20.0) – – – – – – –
CEMCAT – Barcelona
NC 166 32.3 (8.4) 127/39 (76.5) 5.7 (3.7) 75/43/26/22 12.0 76/164 (46.3) 5.9 (23.1) 37.9 (14.5) 0.7 (0.5)
C 166 28.8 (7.3) 114/52 (68.7) 9.1 (3.3) 59/38/54/15 75.3 127/165 (76.9) 7.3 (10.9) 37.9 (17.0) 1.0 (0.6)
Non-INDC 93 41.5 (17.0) 53/34 (60.9) – – – – – – –
INDC 6 33.3 (11.0) 4/1 (80.0) – – – – – – –
IMU – Innsbruck
NC 28 34.6 (10.1) 19/9 (67.8) 2.5 (1.4) 8/6/9/5 17.9 28/28 (100) 14.0 (14.8) 40.4 (13.0) 1.2 (0.7)
C 19 29.6 (7.5) 14/5 (73.7) 3.5 (1.3) 4/7/6/2 10.5 19/19 (100) 12.5 (11.3) 42.2 (13.3) 1.1 (0.7)
Non-INDC 58 50.1 (15.0) 38/20 (65.5) – – – – – – –
INDC 48 47.0 (20.7) 17/31 (35.4) – – – – – – –
KUH – Solna
NC 26 39.3 (10.9) 20/6 (76.9) 2.9 (3.7) 7/5/7/7 0 14/26 (53.8) 4.7 (6.0) NA 0.6 (0.2)
C 37 33.0 (8.3) 29/8 (78.4) 5.5 (3.1) 11/5/11/10 0 33/37 (89.2) 8.4 (6.4) NA 0.9 (0.4)
Non-INDC 47 41.1 (13.1) 31/16 (65.9) – – – – – – –
INDC 0 – – – – – – – – –
Summary
NC 394 33.9 (9.7) 296/98 (75.1) 4.2 (3.2) 163/84/88/59 20.6 243/377 (64.4) 9.2 (19.7) 36.5 (13.8) 0.8 (0.5)
C 419 30.6 (8.1) 297/122 (70.9) 6.4 (3.7) 132/97/123/65 45.1 344/407 (84.5) 9.9 (15.2) 39.2 (18.6) 1.0 (0.6)
Non-INDC 438 43.6 (16.6) 249/183 (57.6) – – – – – – –
INDC 121 44.7 (18.3) 51/69 (42.5) – – – – – – –
Data are expressed as mean (standard deviation), except for the follow-up time which is expressed as median (interquartile range).
aClinical presentation and data indicate the number of patients for each CIS type: ON = optic neuritis; BS = brainstem; SP = spinal; OT = other topographies.
bPercentage of patients who received immunomodulatory treatment between the CIS event and the date of conversion to multiple sclerosis for converters, and during follow-up time
for non-converters. The variability in the percentage of treated CIS patients probably reflects the use of different criteria to initiate immunomodulatory treatment across multiple
sclerosis centres. Of 792 CIS patients, 71 (9.0%) received corticosteroid treatment within the month prior to lumbar puncture (information was missing in 21 patients). Two of 813
CIS patients (0.2%) were receiving immunomodulators at the time of lumbar puncture. These two variables (treatment with corticosteroids and immunomodulators) did not remain
significant in the multivariable Cox regression models.
cn = number of patients with positive oligoclonal bands / N = total number of patients in whom oligoclonal bands (OB) were determined (percentage of positive patients). Ten per
cent of the patients included in the validation study from the CEMCAT cohort also participated in the previous proteomic study (Comabella et al., 2010).
dInformation on treatment not available for six patients.
eInformation on CIS type not available for two patients.
Centre abbreviations: HC – Barcelona = Hospital Clı´nic, Barcelona; HRC – Madrid = Hospital Ramo´n y Cajal, Madrid; UULM – Ulm = University of Ulm, Ulm; EUMC –
Rotterdam = Erasmus University Medical Centre, Rotterdam; GM – Madrid = Hospital Gregorio Maran˜o´n, Madrid; PH – Madrid = Hospital Puerta de Hierro, Madrid; HP –
Toulouse = Hoˆpital Purpan, Toulouse; OP – Milan = Ospedale Policlinico, Milan; USB – Basel = University Hospital, University of Basel, Basel; MUL – Lublin = Medical University of
Lublin, Lublin; CU – Prague = Charles University, Prague; MU – Graz = Medical University of Graz, Graz; CEMCAT – Barcelona = Centre d’Esclerosi Mu´ltiple de Catalunya,
Barcelona; IMU – Innsbruck = Innsbruck Medical University, Innsbruck; KUH – Solna = Karolinska University Hospital, Solna.
Converters (C) and non-converters (NC) refer to CIS patients who converted and who did not convert to multiple sclerosis by Poser criteria, respectively; NA = data not available.
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for 1 h at 4C and washed. Finally, cells were incubated with
streptavidin-PE for 45min at 4C.
Samples were analysed on a standard FACSCanto II instru-
ment (Becton Dickinson). An initial region was set around cells
expressing intermediate to high CD45 with low to intermedi-
ate side scatter (P1) and then a second region was set on the
forward/side scatter dot plot to exclude debris or apoptotic
cells (P2). Only cells included in P1 and P2 regions were ac-
cepted for analysis. Monocytes were then selected by gating
side scatter versus CD14 expression to identify CD14 low
(CD14low) and CD14 high (CD14high) subsets, and T cells by
gating side scatter versus CD3 expression. Representative ex-
amples of gating strategy and of anti-CHI3L1 and control
isotype staining in the three cell subsets are shown in
Supplementary Fig. 1. The speciﬁcity of anti-CHI3L1 antibody
staining was assessed by means of blocking experiments incu-
bating 1 mg of anti-CHI3L1 antibody with 2mg of human re-
combinant CHI3L1 protein (TP303769 Origene) for 30min at
4C before cell labelling, and resulted in a clear inhibition of
CHI3L1 staining (Supplementary Fig. 2).
Statistical analysis
Statistical analysis was performed by using the SPSS 17.0 pack-
age (SPSS) for MS-Windows. Considering that CSF CHI3L1
levels were not normally distributed and age-dependent
(Spearman rank correlation coefﬁcient with age: 0.330,
P-value: 5.2  1036; Supplementary Fig. 3), a Mann-
Whitney’s U-test was used to compare age-adjusted CSF
CHI3L1 levels between CIS patients and controls with other
neurological disorders. Receiver operating characteristic (ROC)
curve analyses were used to determine the best cut-off value
based on CSF CHI3L1 levels. Univariate and multivariable
Cox proportional hazard regression models including number
of Barkhof criteria at baseline MRI, presence of IgG oligoclonal
bands, treatment, and age at CIS onset as covariates were used
to evaluate the association between CSF CHI3L1 levels and time
to multiple sclerosis based on Poser or McDonald criteria, and
time to reach EDSS 3.0. Time to multiple sclerosis based on
Poser and McDonald criteria, and time to reach EDSS 3.0 in
patients with high and low CSF CHI3L1 levels were assessed by
Kaplan–Meier survival analysis with Log Rank test.
A Mann-Whitney’s U-test was used to evaluate signiﬁcant dif-
ferences in age-adjusted CSF CHI3L1 levels between patients
with different categories of T2 lesion burden and brain inﬂam-
mation, and differences in CHI3L1 expression by CSF CD3+ T
cells and CD14+ monocytes between multiple sclerosis patients
and controls. Partial correlations adjusted for age were used to
assess the relationship between CSF CHI3L1 levels and (i) the
albumin CSF/serum ratio; (ii) CSF characteristics such as number
of cells, protein concentration, and IgG index; and (iii) change in
brain parenchymal fraction at 1 and 5 years of follow-up.
Results
Clinical characteristics of the CIS
cohort
Mean and median follow-up times of patients with CIS
were 5.4 and 4.6 years, respectively. Of 813 patients, 419
(51.5%) converted to multiple sclerosis by Poser criteria
and 394 remained as CIS during follow-up. A total of
486 patients (60%) converted to multiple sclerosis by
McDonald criteria and 327 continued as CIS. The most
frequent clinical presentation of patients with CIS was
optic neuritis (36.4%), followed by spinal (26.0%), brain-
stem (22.3%), and CIS of other topography (15.3%). IgG
oligoclonal bands were positive in 587 (75%) of 784 pa-
tients. Of 609 patients, 96 (16%) reached an EDSS of 3.0
during follow-up. A total of 269 patients (33.3%) received
immunomodulatory treatment between the CIS event and
the date of conversion to multiple sclerosis for converters,
and during follow-up time for non-converters. Clinical
characteristics of CIS patients stratiﬁed by participating
centre and conversion to multiple sclerosis are detailed in
Table 1.
CSF CHI3L1 levels are increased in
patients with CIS who convert to
clinically definite multiple sclerosis
As a ﬁrst step, we compared CSF CHI3L1 levels between
the whole cohort of CIS patients and control subjects with
other neurological disorders. As depicted in Fig. 1A,
CHI3L1 levels were higher in CIS patients than in non-
inﬂammatory controls (P = 1.8  1027). However, the
highest CHI3L1 levels were observed in inﬂammatory con-
trols, and differences were statistically signiﬁcant when
compared with patients with CIS (P = 3.2  109) and
non-inﬂammatory control subjects (P = 1.9  1019).
Further stratiﬁcation of the CIS group revealed signiﬁcantly
higher CSF CHI3L1 levels in patients with CIS who con-
verted to clinically deﬁnite multiple sclerosis compared to
patients who remained as CIS (P = 8.1  1011; Fig. 1B).
CSF CHI3L1 levels are an
independent risk factor for
conversion to multiple sclerosis
and development of disability
Supplementary Fig. 4 shows the areas under the ROC curve
(AUC) of CSF CHI3L1, which were signiﬁcant for time to
multiple sclerosis based on Poser criteria [AUC = 0.59;
95% conﬁdence interval (CI) 0.55–0.63; P = 1.4  105]
and McDonald criteria (AUC = 0.61; 95% CI 0.57–0.65;
P = 9.7  108), and for time to EDSS 3.0 (AUC = 0.70;
95% CI 0.64–0.76; P = 5.1  1010). A CHI3L1 value of
170 ng/ml resulted in the best cut-off point to classify CSF
protein levels into high and low. For this cut-off, sensitivity
and speciﬁcity were 51.8.% and 63.7%, respectively for
time to multiple sclerosis by Poser criteria; 51.2% and
66.1% for time to multiple sclerosis by McDonald criteria;
and 74.0% and 60.0% for time to EDSS 3.0.
A total of 360 CIS patients (44.3%) had CHI3L1 levels
above the cut-off value. We ﬁrst investigated the
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association between CSF CHI3L1 levels stratiﬁed according
to the cut-off value and time to conversion to multiple
sclerosis and time to reach EDSS 3.0 in univariate and
multivariable Cox regression models adjusted by the
number of Barkhof criteria at baseline MRI, presence of
oligoclonal bands, treatment, and age at CIS onset. As
shown in Fig. 2, CSF CHI3L1 levels were an independent
risk factor for conversion to multiple sclerosis based on
Poser criteria [hazard ratio (HR) = 1.69; P = 1.1  105]
or McDonald criteria (HR = 1.61; P = 3.7  106).
Interestingly, CSF levels of CHI3L1 were the only signiﬁ-
cant independent risk factor associated with the develop-
ment of disability (HR = 3.82; P = 5.3  108).
High CSF CHI3L1 levels are asso-
ciated with shorter time to multiple
sclerosis and more rapid develop-
ment of disability
We next examined time to multiple sclerosis and time to
reach EDSS 3.0 in patients with high and low CSF CHI3L1
levels by Kaplan–Meier survival analysis. As depicted in
Fig. 3, high CSF CHI3L1 levels were associated with
shorter time to multiple sclerosis based on Poser criteria
(log-rank P-value = 3.2  109) or McDonald criteria
(P = 5.6  1011). Similarly, when the time to reach an
EDSS of 3.0 was evaluated, high CSF CHI3L1 levels
were associated with more rapid development of disability
(P = 1.8  1010).
Overall, high CSF CHI3L1 levels were also associated
with a worse prognosis in patients with CIS classiﬁed ac-
cording to the presence or absence of IgG oligoclonal bands
and MRI abnormalities (Supplementary Fig. 5). When CIS
patients were classiﬁed according to treatment, high CSF
CHI3L1 were associated with earlier disability progression
in both untreated and treated patients; however, signiﬁcant
differences were lost in the treated group when time to
multiple sclerosis was evaluated (Supplementary Fig. 6).
Finally, time to reach an EDSS of 3.0 was shorter in CIS
patients who converted to multiple sclerosis based on Poser
or McDonald criteria and had high CSF CHI3L1 levels
compared to non-converters (Supplementary Fig. 7).
CSF CHI3L1 levels are associated
with brain MRI abnormalities at
baseline and with the development of
brain atrophy during follow-up
CSF CHI3L1 levels reﬂected the degree of brain inﬂamma-
tion and lesion burden in MRI scans performed at the time
of the CIS event. As shown in Fig. 4A, CHI3L1 levels were
signiﬁcantly higher in patients with gadolinium enhancing
lesions than in patients without enhancing lesions
(P = 1.4  107), and in patients with nine or more T2
lesions compared to patients with one to eight lesions
(P = 3.4  104) and patients with no T2 lesions
(P = 2.5  105).
In the subgroup of CIS patients with data on brain atro-
phy during follow-up, CSF CHI3L1 levels correlated signiﬁ-
cantly with brain parenchymal fraction change after 1 year
(r = 0.25; P = 0.04) and 5 years (r = 0.38; P = 0.002).
CHI3L1 levels in CSF are primarily
brain derived and correlate with
inflammatory CSF parameters
To evaluate the relationship between CSF CHI3L1 levels
and blood-CSF barrier dysfunction, the albumin CSF/
serum ratio was analysed in CSF samples from a subgroup
of CIS patients. As illustrated in Fig. 4B, CHI3L1 protein
levels were little inﬂuenced by the albumin CSF/serum ratio
(r = 0.04; P = 0.795), indicating that CSF CHI3L1 protein
is mainly brain-derived.
CSF CHI3L1 levels correlated weakly with CSF charac-
teristics such as number of cells (r = 0.11; P = 0.008),
Figure 1 Comparison of CSF CHI3L1 levels among groups. Boxplots showing CSF levels of CHI3L1 in the whole CIS group and
inflammatory and non-inflammatory neurological controls (A), and in CIS patients who converted to clinically definite multiple sclerosis (CDMS)
and patients who continued as CIS (B). CSF CHI3L1 levels were age-adjusted and then compared among groups by a Mann-Whitney U-test.
Parentheses indicate number of individuals included within each group. CIS = whole CIS cohort; C = CIS patients who converted to clinically
definite multiple sclerosis (clinically definite multiple sclerosis); NINDC = non-inflammatory neurological disease controls; INDC = inflammatory
neurological disease controls; NC = CIS patients who did not convert to clinically definite multiple sclerosis during follow-up.
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protein concentration (r = 0.13; P = 0.002), and IgG index
(r = 0.20; P = 5.8  106).
CHI3L1 is expressed by reactive
astrocytes and macrophages/
microglia from brain tissue and
CD14low monocytes from CSF
As a last step, we investigated the CHI3L1 cell source in
brain tissue and CSF from multiple sclerosis patients. In
chronic active lesions with high inﬂammatory activity,
CHI3L1 immunostaining was more intense and located at
the edge of the lesions and in the demyelinated area (Fig.
5A and G), whereas in lesions with low inﬂammatory ac-
tivity CHI3L1 immunostaining was less intense and mainly
restricted to the demyelinated area (Fig. 5A and H). In
contrast, non-neurological control brain samples were
negative for CHI3L1 staining (Fig. 5A and I). Double
immunostainings in lesions with high inﬂammatory activity
revealed CHI3L1 expression by reactive astrocytes
(GFAP+ cells; Fig. 5A and J) and macrophages/microglial
cells (CD68 + cells; Fig. 5A and M). In lesions with low
inﬂammatory activity, CHI3L1 expression was restricted to
the cytoplasm of few macrophages/microglial cells (CD68 +
cells; Fig. 5A and N). T lymphocytes (CD3+ cells) were
Figure 2 Analysis of the prognostic role of CSF CHI3L1 levels in CIS patients. Results of univariate and multivariable Cox regression
analyses investigating the association between CSF CHI3L1 levels and time to conversion to multiple sclerosis (MS) and time to reach EDSS 3.0.
For conversion to multiple sclerosis based on Poser criteria and time to EDSS 3.0, multivariable Cox regression model was adjusted by the
number of Barkhof criteria at baseline MRI, presence of oligoclonal bands, treatment, and age at CIS onset. For conversion to multiple sclerosis
based on McDonald criteria, considering that the number of Barkhof criteria is included in the McDonald criteria for conversion to multiple
sclerosis, multivariable analysis was adjusted by the presence of oligoclonal bands, treatment, and age at CIS onset but not by baseline Barkhof
criteria. CHI3L1 levels: CSF CHI3L1 levels stratified according to a cut-off value of 170 ng/ml. Barkhof criteria: number of Barkhof criteria recoded
into two categories: 0, 1, 2 Barkhof criteria and 3, 4 Barkhof criteria. OB = presence or absence of IgG oligoclonal bands; Age = age at CIS onset.
Treatment refers to whether patients received treatment between the CIS event and the date of conversion to multiple sclerosis for converters,
and during follow-up time for non-converters.
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Figure 4 Association between CSF CHI3L1 levels and MRI abnormalities and CSF characteristics. (A) Boxplots showing age-
adjusted CSF CHI3L1 levels in CIS patients stratified according to the presence of gadolinium (Gd) enhancing lesions (left) and number of T2
lesions (right) at baseline. The number of Gd enhancing lesions was recoded into two categories: 0 lesions / 1 or more lesions. The number of T2
lesions was recoded into three different categories: 0 lesions / 1–8 lesions / 9 or more lesions. Numbers in parentheses indicate individuals
available for analysis. Analysis was performed with a Mann-Whitney’s U-test. (B) Relationship between the albumin CSF/serum ratio (Q alb) and
CHI3L1 protein levels in CSF. Albumin CSF/serum ratio was analysed in a subgroup of 59 CIS patients (40 patients from the University of Basel,
Switzerland; and 19 patients from the University of Ulm, Germany). r = partial correlation coefficient.
Figure 3 Kaplan-Meier curves for time to multiple sclerosis and time to EDSS 3.0 according to baseline CSF CHI3L1 levels
classified into high and low based on a cut-off value of 170 ng/ml. Graphs show log-rank P-values. Numbers represent patients at risk for
the different follow-up times. Tables indicate median times (95% CI) to multiple sclerosis and EDSS 3.0 in CIS patients with high and low CHI3L1
levels.
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persistently negative for CHI3L1 immunostaining (Fig. 5A,
P and Q).
When CHI3L1 expression was explored by ﬂow cytome-
try in CSF cells, protein expression was restricted to mono-
cytes (CD14 + cells) from patients with multiple sclerosis
and non-inﬂammatory controls, being higher in the mul-
tiple sclerosis group (P = 0.008 versus non-INDC; Fig. 5B
and C). In contrast, CHI3L1 expression was absent in T
cells (CD3+ cells) from multiple sclerosis patients and con-
trols (Fig. 5B and C). Interestingly, monocytes with low
expression of CD14 (CD14low) were the major CSF cell
subset expressing CHI3L1, particularly in the multiple
sclerosis group (P = 0.008 when compared with non-
INDC; Fig. 5C).
Discussion
CHI3L1 [also known as YKL-40, human cartilage
glycoprotein 39 (HC-gp39), breast regression protein 39
Figure 5 CHI3L1 expression in brain tissue and CSF cells. (A) CHI3L1 expression in chronic active lesions from multiple sclerosis
patients and controls. Sections were stained with haematoxylin and eosin (HE; A–C) and Klu¨ver-Barrera (KB; D–F), and subsequently classified
into lesions with high inflammatory activity (A and D) and low inflammatory activity (B and E). Arrowheads indicate inflammatory infiltration
observed at the edge of the lesions and arrows show perivascular inflammatory infiltration. Control samples did not show inflammatory cells or
demyelination (C and F). CHI3L1 expression was observed at the edge of multiple sclerosis lesions (arrowheads) and in the demyelinated area
(arrows) (G and H) but not in control samples (I). CHI3L1 expression was present in the cytoplasm of astrocytes (GFAP + ) only in high
inflammatory activity lesions (J–L), while it was observed within macrophages/microglial cells (CD68 + cells) in both types of lesions (M–O). T
lymphocytes (CD3 + ) did not show CHI3L1 expression (P–R). (B) CHI3L1 expression in CSF cells from multiple sclerosis patients (n = 5) and
non-inflammatory controls (n = 5; optic neuropathy, head trauma, arachnoid cyst, and two controls with neuropathies). Top: Representative dot
plots showing gating strategy. An initial region (P1) was set on the forward/side scatter dot plot to include mononuclear cells and exclude debris
or apoptotic cells. A second region was set around cells expressing intermediate to high CD14 with intermediate side scatter (monocytes, P2),
and a third one around cells negative for CD14 with low side scatter (lymphocytes, P3). Middle and bottom: Representative dot plots showing
intracellular CHI3L1 expression in monocytes (CD14 + cells) and T cells (CD3 + cells) respectively from a multiple sclerosis patient (left) and a
control (right). (C, left) Bar graph showing the percentage of monocytes (CD14 + cells) and T cells (CD3 + cells) expressing CHI3L1 in multiple
sclerosis patients (MS, n = 5) and non-INDC (NINDC, n = 5). Right: Bar graph showing CHI3L1 expression in monocytes classified according to
CD14 expression: CD14 high (CD14high) and CD14 low (CD14low). A Mann-Whitney U-test was used to evaluate significant differences in
CHI3L1 expression by CD3 + T cells and CD14 + monocytes between multiple sclerosis patients and controls.
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(BRP-39)], is a member of the family of chitinases and
chitinase-like proteins containing a highly conserved
glyco-18 domain as common feature (Kzhyshkowska
et al., 2007). For these proteins, chitin is the only docu-
mented substrate (Kzhyshkowska et al., 2007). However,
whereas other chitinases of the family such as chitotriosi-
dase and acidic mammalian chitinase AMCase have
demonstrated chitinolytic activity (Renkema et al., 1995;
Boot et al., 2001), CHI3L1 can bind chitin but lacks chit-
inolytic activity (Hakala et al., 1993).
CHI3L1 is expressed by different cell types, including
chondrocytes (Hakala et al., 1993), vascular smooth
muscle cells (Shackelton et al., 1995), airway epithelial
cells (Park et al., 2010), neutrophils (Volck et al., 1998),
and macrophages (Renkema et al., 1998). In the CNS,
CHI3L1 expression has been mainly observed in astrocytes
of monkeys and humans with lentiviral encephalitis
(Bonneh-Barkay et al., 2008), and patients with brain in-
farct (Bonneh-Barkay et al., 2010).
Increased circulating levels of CHI3L1 have been re-
ported in a wide variety of heterogeneous conditions char-
acterized by chronic inﬂammation such as rheumatoid
arthritis (Peltomaa et al., 2001), osteoarthritis (Vos et al.,
2000), inﬂammatory bowel disease (Vind et al., 2003), sys-
temic lupus erythematosus (Vos et al., 2000), asthma
(Chupp et al., 2007), sarcoidosis (Johansen et al., 2005),
hepatic ﬁbrosis (Johansen et al., 2000), atherosclerosis
(Michelsen et al., 2010), type 2 diabetes (Persson et al.,
2012), and obesity (Hempen et al., 2009); in many in-
stances, serum or plasma CHI3L1 levels correlated with
disease activity and severity (Johansen et al., 2000, 2005;
Vos et al., 2000; Peltomaa et al., 2001; Vind et al., 2003;
Chupp et al., 2007; Persson et al., 2012). Circulating levels
of CHI3L1 have also been found to be elevated in an ex-
tensive range of primary and metastatic cancers, including
tumours of the ovary (Dupont et al., 2004), endometrium
(Peng et al., 2010), breast (Jensen et al., 2003), prostate
(Brasso et al., 2006), stomach (Bi et al., 2009), colon/
rectum (Cintin et al., 1999), lung (Thom et al., 2010),
and brain (Iwamoto et al., 2011), in which CHI3L1
levels were associated with poorer survival of cancer
patients.
Regarding CNS disorders, serum levels of CHI3L1 were
found to be increased in patients with stroke and correlated
with functional outcome (Park et al., 2012); plasma and
CSF CHI3L1 levels were reported to have diagnostic impli-
cations in patients with preclinical and early Alzheimer’s
disease (Craig-Schapiro et al., 2010; Choi et al., 2011;
Perrin et al., 2011); CSF CHI3L1 levels were found to be
elevated in patients with relapsing-remitting multiple scler-
osis (Correale and Fiol, 2011), and plasma CHI3L1 levels
were associated with the progressive forms of multiple
sclerosis (Canto et al., 2012).
Despite the numerous studies showing an implication of
CHI3L1 in numerous disorders, its mechanism of action
remains poorly understood, beyond few studies suggesting
a function of CHI3L1 as tissue remodelling factor (Rehli
et al., 1997; Badariotti et al., 2006; Bigg et al., 2006).
However, irrespective of this ignorance in its biophysiolo-
gical activity, the abovementioned studies clearly point to a
role of CHI3L1 as prognostic biomarker in a wide variety
of conditions.
The potential role of CHI3L1 as prognostic biomarker in
patients with CIS emerged from a screening proteomic
study in a Spanish cohort in which CSF CHI3L1 levels
were found to be elevated in patients who converted to
clinically deﬁnite multiple sclerosis compared to those
who continued as CIS (Comabella et al., 2010). These ini-
tial ﬁndings have now been validated in a much larger
cohort of CIS patients from different European multiple
sclerosis centres, and CSF CHI3L1 levels were found
again to be increased in CIS patients who later converted
to clinically deﬁnite multiple sclerosis. The highest CSF
levels of CHI3L1 were, however, observed in inﬂammatory
controls, a ﬁnding somehow expected considering that a
large proportion of these controls were suffering from
CNS infectious diseases such as meningitis and encephalitis,
conditions associated with extremely elevated CSF CHI3L1
levels (Ostergaard et al., 2002). When the role of CHI3L1
as biomarker associated with the conversion to multiple
sclerosis was further explored in multivariable Cox regres-
sion models, CSF CHI3L1 levels resulted in a risk factor for
conversion to multiple sclerosis independent of strong pre-
dictors of conversion to multiple sclerosis such as brain
MRI abnormalities and IgG oligoclonal bands (Tintore
et al., 2006, 2008; Fisniku et al., 2008).
The long-term follow-up of some CIS patients included in
the study allowed us to explore the role of CHI3L1 in the
development of disability by examining the time to reach
an EDSS score of 3.0. It is important to highlight that CSF
CHI3L1 levels were a strong predictor of disability progres-
sion and, in fact, they were the only signiﬁcant independent
risk factor associated with the development of disability in
multivariate Cox regression models.
Over 40% of patients with CIS had CSF CHI3L1 levels
4170 ng/ml, a cut-off point with clear prognostic implica-
tions insomuch as patients with CHI3L1 levels above the
cut-off value had earlier conversion to multiple sclerosis
and earlier disability progression. This cut-off value of
CSF CHI3L1 levels can be applied to clinical settings to
identify those CIS patients with worse disease prognosis.
The ﬁnding of high CSF CHI3L1 values, together with in-
formation from other variables such as the presence of IgG
oligoclonal bands or three of four Barkhof criteria in the
baseline MRI may aid the neurologist in the clinical deci-
sion-making of initiating treatment. While the behaviour of
CHI3L1 as biomarker associated with conversion to mul-
tiple sclerosis is probably modest and not much different
from other study variables, its role as prognostic biomarker
is particularly relevant when the time to reach EDSS 3.0 is
analysed, insomuch as CSF CHI3L1 levels above the
170 ng/ml cut-off were conferring, as a unique predictor,
a 4-fold increased risk for the development of disability.
Moreover, high CSF CHI3L1 levels were associated with
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earlier disability progression (5-year difference as median
time to reach EDSS 3.0 compared to patients with low
protein values) with sensitivity over 70%. Based on this,
CIS patients with high CSF CHI3L1 levels at the baseline
lumbar puncture may beneﬁt from early treatment to delay
future development of disability.
The association between CSF CHI3L1 levels and both
MRI abnormalities and CSF parameters at the time of the
CIS event point to a close relationship between CHI3L1
levels and the degree of inﬂammation in the CNS of CIS
patients. This relationship probably also explains the sig-
niﬁcant correlations observed between CHI3L1 levels and
brain atrophy during follow-up; however, given the rela-
tively small number of patients with brain atrophy data
in the study, the role of CHI3L1 in the development of
brain atrophy needs to be conﬁrmed in larger cohorts of
CIS patients and at longer time points.
The abovementioned association between CHI3L1 levels
and CNS inﬂammation may prompt one to speculate that
the blood-borne CNS inﬂammatory cell inﬁltration is the
most likely source of CSF CHI3L1 levels. However, both
albumin CSF/serum ratio data and immunohistochemistry
ﬁndings argued against this hypothesis and suggest a pri-
marily local CNS origin of CSF CHI3L1 levels. First, the
independent behaviour of CSF CHI3L1 levels from the al-
bumin CSF/serum ratio, a well-established measure for
blood-CSF barrier dysfunction (Brettschneider et al.,
2005), indicates that CSF CHI3L1 protein is mainly brain
derived. This notion is further supported by the 6-fold dif-
ference observed in CHI3L1 protein levels between CSF
and serum samples (Comabella et al., 2010). In conse-
quence, CSF levels of CHI3L1 do not require any correc-
tion for blood concentration or albumin CSF/serum ratio,
while necessary for blood-derived proteins such as IgG
(Link and Tibbling, 1977). Second, CHI3L1 expression in
multiple sclerosis chronic active lesions with high inﬂam-
matory activity largely derived from astrocytes, a ﬁnding
already reported in a previous study (Bonneh-Barkay
et al., 2010). A contribution of blood-derived cells to
CSF CHI3L1 levels cannot be ruled out based on the ﬁnd-
ing of CHI3L1 expression by CD68 positive macrophages/
microglial cells in brain tissue and CD14 positive mono-
cytes in CSF. However, the fact that CHI3L1 expression
was mainly observed in CSF CD14low monocytes, a cell
population reported to have decreased migratory potential
to inﬂamed tissues due to the lack of chemokine receptor
CCR5 (Geissmann et al., 2003; Sunderkotter et al., 2004;
Louboutin et al., 2011; Rossol et al., 2012), suggests that
CHI3L1 expression by CD14low monocytes is possibly not
related to the blood-derived CNS inﬂammatory cell inﬁltra-
tion and these cells may be playing more critical roles in
replacing resident macrophages (Geissmann et al., 2003).
It can be hypothesized that brain macrophages/microglial
cells and CSF CD14low monocytes are responsible for a low-
level basal expression of CHI3L1 in the CNS, which can be
further increased in proportion to the CNS inﬂammatory
insult by the contribution of additional cells, primarily
astrocytes. In these cases, the higher CSF CHI3L1 levels
would reﬂect the degree of astrocyte activation secondary to
inﬂammation. This is supported by the ﬁnding of CHI3L1
expression by reactive astrocytes in brain lesions with high
inﬂammatory activity, and the positive correlations observed
between CSF CHI3L1 levels and MRI abnormalities and in-
ﬂammatory CSF parameters. The fact that high CSF CHI3L1
levels are associated with worse prognosis of CIS patients
indirectly suggests a detrimental role of astrocyte activation
in multiple sclerosis pathogenesis.
In conclusion, the aggregate results from this study con-
ﬁrm the prognostic role of CHI3L1 as biomarker asso-
ciated with the conversion to multiple sclerosis and the
development of disability in CIS patients. We propose to
measure CSF CHI3L1 levels in CIS patients to identify
those individuals with worse disease prognosis. The study
also becomes the ﬁrst example of large-scale validation of a
CSF candidate biomarker in the ﬁeld of multiple sclerosis.
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